Illumina's Q4 Revenues Rise 86 Percent; Legal Expenses Hit Bottom Line | GenomeWeb
This article has been updated to include comments from a conference call, financial guidance, and a stock update.
 
NEW YORK (GenomeWeb News) – Illumina yesterday reported an 86 percent increase in revenues for the fourth quarter ended Dec. 31, 2007, while its profit swung to a loss due to legal expenses associated with a recent settlement with Affymetrix.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.